iShares MSCI Indonesia ETF (EIDO) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $19.2252W High
- $10.8052W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track iShares MSCI Indonesia ETF (EIDO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares MSCI Indonesia ETF has traded between a low of $10.8 and a high of $19.22, highlighting its annual price range. Buy and sell iShares MSCI Indonesia ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Most Recent News
OpenAI halts work on Astra model after it shows risky cybersecurity capabilities.
OpenAI has paused development on its upcoming AI model Astra after internal tests revealed it could independently execute cyberattacks on secure systems, triggering the company's cybersecurity safeguards. This move follows a recent incident where ano...
Medline stock drops over 19% after FDA cites major manufacturing violations and lowers earnings forecast.
Medline Inc. faced significant FDA violations related to manufacturing quality, including failure to investigate contamination and cleaning issues, leading to a stock drop of over 7% initially. The stock further fell by more than 12% following disapp...
Aberdeen Healthcare Investors fund offers 56% NAV return and 12% distribution, trading at 6.4% discount.
Aberdeen Healthcare Investors (HQH) is a biotech-focused closed-end fund trading at a 6.4% discount to its net asset value (NAV). Over the past year, the fund delivered a strong 56% NAV return, benefiting from favorable FDA regulatory changes and mer...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.